Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai Gynecologic Oncology Group
With
Fudan University
Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital
This exploratory trial is to compare the efficacy of sequential chemotherapy, intraperitoneal chemotherapy followed by intravenous chemotherapy, versus intravenous chemotherapy alone in the first-line therapy for ovarian cancer.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years to ≤ 75 years.
Epithelial ovarian cancer with pathology confirmed stage IIIc or IV, expect for lymph node metastasis alone
Optimal cytoreductive surgery, including hysterectomy, bilateral salpinges-oophorectomy, omentectomy, and resection of all metastatic lesions, with a residual disease no more than 1cm
Available to receive intraperitoneal chemotherapy 5-10 days postoperative, or no more than postoperative 14 days for those with bowel resection.
ECOG performance 0-2.
No more than 3 cycles of chemotherapy prior to surgery.
Laboratory testing within 7 days of registration: hematopoietic: absolute neutrophil count greater than 1,500/mm3; Platelet count greater than 100,000/mm3. Hepatic: bilirubin less than 1.25 times upper limit of normal (ULN); Bilirubin \< 2.0, SGPT less than 2 times ULN. Renal: creatinine less than 1.6 mg/dL, OR creatinine clearance greater than 40 mL/min.
Comply with intraperitoneal chemotherapy and follow-up.
